Pancreatic Cancer Research

ResearcherTongji HospitalActive in the last 2 years

Jun Gong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9744-7201; OpenAlex author ID A5084571872, A5102496392. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 8

  1. Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and stabilizing BAG3. First author DOI 10.1038/s41418-026-01665-1↗
  2. Navigating the complexities of ferroptosis in pancreatic ductal adenocarcinoma: roles, mechanisms and potential applications. Last author DOI 10.1038/s41420-026-02987-2↗
  3. Identification of a fibroblast-derived gene signature reveals prognostic and therapeutic insights in pancreatic cancer. Co-author DOI 10.1007/s10238-025-01801-0↗
  4. The multifaceted roles of deubiquitinating enzymes (DUBs) in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-025-08052-7↗
  5. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41418-022-01040-w↗
  6. An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1332626↗
  7. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. Co-author DOI 10.1186/s13046-022-02491-2↗
  8. Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s12943-020-01249-8↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Wang · 6 shared papers, 2020–2026 · strength 1.08
  2. Renyi Qin · 6 shared papers, 2020–2026 · strength 1.08
  3. Yuhui Liu · 3 shared papers, 2023–2026 · strength 0.91
  4. Min Zhou · 4 shared papers, 2023–2026 · strength 0.86
  5. Zhenxiong Zhang · 4 shared papers, 2022–2026 · strength 0.71
  6. Shutao Pan · 4 shared papers, 2022–2026 · strength 0.71
  7. Taoyuan Yin · 4 shared papers, 2022–2026 · strength 0.71
  8. Chunle Zhao · 3 shared papers, 2022–2026 · strength 0.55
  9. Yongkang Shi · 3 shared papers, 2022–2026 · strength 0.55
  10. Yurao Xiao · 1 shared paper, 2026 · strength 0.39
  11. Xingjun Guo · 3 shared papers, 2020–2023 · strength 0.38
  12. Wenjia Wang · 1 shared paper, 2025 · strength 0.37
  13. Guangbing Xiong · 1 shared paper, 2025 · strength 0.28
  14. Yu Bai · 1 shared paper, 2026 · strength 0.26
  15. Min Zhou · 1 shared paper, 2022 · strength 0.13
  16. Li Xu · 1 shared paper, 2020 · strength 0.08
  17. Yan Zhao · 1 shared paper, 2020 · strength 0.08
  18. Shuo Yu · 1 shared paper, 2020 · strength 0.08
  19. Xiaodong Xu · 1 shared paper, 2020 · strength 0.08
  20. Chengjian Shi · 1 shared paper, 2020 · strength 0.08
  21. Ruizhi He · 1 shared paper, 2020 · strength 0.08
  22. Min Li · 1 shared paper, 2020 · strength 0.08
  23. Jianxin Jiang · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.